Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
7(50%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_3
1
7%
Ph phase_2
3
21%
Ph not_applicable
1
7%
Ph phase_1
4
29%
Ph early_phase_1
4
29%

Phase Distribution

8

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
4(30.8%)
Phase 1Safety & dosage
4(30.8%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
1(7.7%)
N/ANon-phased studies
1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

14

all time

Status Distribution
Active(7)
Completed(4)
Other(3)

Detailed Status

Recruiting7
Completed4
unknown3

Development Timeline

Analytics

Development Status

Total Trials
14
Active
7
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 14 (30.8%)
Phase 14 (30.8%)
Phase 23 (23.1%)
Phase 31 (7.7%)
N/A1 (7.7%)

Trials by Status

unknown321%
completed429%
recruiting750%

Recent Activity

7 active trials
Showing 5 of 14
recruitingphase_2

Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

NCT02019706
recruitingphase_1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT06479811
recruitingphase_2

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

NCT07284589
completed

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

NCT04069299
recruitingphase_1

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

NCT06427798
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT02019706Phase 2

Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

Recruiting
NCT06479811Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Recruiting
NCT07284589Phase 2

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Recruiting
NCT04069299

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Completed
NCT06427798Phase 1

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Recruiting
NCT01879657Not Applicable

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Completed
NCT06056362Phase 1

Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors

Recruiting
NCT01873248Early Phase 1

Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

Completed
NCT04847505Phase 3

68Ga-DOTA-TATE PET/CT Imaging in NETs

Recruiting
NCT05069220Early Phase 1

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Recruiting
NCT00001277Phase 2

Studies of Elevated Parathyroid Activity

Completed
NCT04689893Phase 1

Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in the Diagnosis and Evaluation of TIO

Unknown
NCT04041882Early Phase 1

68Ga-DOTATATE PET/CT in Neuroendocrine Tumor

Unknown
NCT01524016Early Phase 1

68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia

Unknown

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14